Skip to main content
Figure 1 | BMC Nephrology

Figure 1

From: Fibroblast growth factor 23 and parathyroid hormone after treatment with active vitamin D and sevelamer carbonate in patients with chronic kidney disease stage 3b, a randomized crossover trial

Figure 1

Delta iFGF23 levels. Box plot of Δ intact fibroblast growth factor 23 (iFGF23): mean iFGF23 level after the first treatment period minus mean iFGF23 level after the second treatment period. Group-1: the alphacalcidol – sevelamer carbonate group: alphacalcidol for two weeks (first treatment period) followed by sevelamer carbonate for two weeks (second treatment period) after two weeks washout. Group-2: the sevelamer carbonate – alphacalcidol group: sevelamer carbonate for two weeks (first treatment period) followed by alphacalcidol for two weeks (second treatment period) after two weeks washout.

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us